BWAY Stock Overview
Develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BWAY from our risk checks.
My Notes
Capture your thoughts, links and company narrative
BrainsWay Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪10.23 |
| 52 Week High | ₪10.98 |
| 52 Week Low | ₪4.61 |
| Beta | 0.40 |
| 1 Month Change | 10.71% |
| 3 Month Change | 7.12% |
| 1 Year Change | 74.87% |
| 3 Year Change | 37.87% |
| 5 Year Change | -8.82% |
| Change since IPO | -7.75% |
Recent News & Updates
Recent updates
BrainsWay: Cash Flow Doubts Weigh On The Stock
Nov 13BrainsWay: Operating Leverage Driving Upside
Aug 13BrainsWay: An Interesting Niche Concern
Jul 22BrainsWay: Profitable, Growing, And Cheap
Mar 07BrainsWay Q4 Earnings Preview
Feb 27BrainsWay gets significant private insurance coverage from Cigna for OCD treatment Utilizing Deep TMS
Sep 14BrainsWay adds 20% on FDA nod for depression therapy
Aug 29Brainsway GAAP EPS of -$0.07 in-line, revenue of $8.01M misses by $0.41M
Aug 10BrainsWay's Shares Look Attractive
Jul 12BrainsWay's Competitive Advantage Is Growing
Jan 21BrainsWay: Still Undervalued (Still)
Jun 02BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment
Apr 26Brainsway: Still Undervalued
Dec 24Brainsway +4% on Q3 beat, bottom-line up 66%
Nov 18Shareholder Returns
| BWAY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.4% | 3.9% | 3.1% |
| 1Y | 74.9% | 12.0% | 23.7% |
Return vs Industry: BWAY exceeded the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: BWAY exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| BWAY volatility | |
|---|---|
| BWAY Average Weekly Movement | 6.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BWAY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BWAY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 134 | Hadar Levy | www.brainsway.com |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.
BrainsWay Ltd. Fundamentals Summary
| BWAY fundamental statistics | |
|---|---|
| Market cap | US$193.73m |
| Earnings (TTM) | US$1.50m |
| Revenue (TTM) | US$38.63m |
129.2x
P/E Ratio5.0x
P/S RatioIs BWAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BWAY income statement (TTM) | |
|---|---|
| Revenue | US$38.63m |
| Cost of Revenue | US$9.82m |
| Gross Profit | US$28.81m |
| Other Expenses | US$27.31m |
| Earnings | US$1.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.04 |
| Gross Margin | 74.57% |
| Net Profit Margin | 3.88% |
| Debt/Equity Ratio | 0% |
How did BWAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 19:16 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BrainsWay Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |